This is a working overview of Primary drying, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
Lyophilized products are typically hygroscopic and require protection from moisture during storage. Manufacturers seal them in glass vials, often under vacuum or an inert gas such as nitrogen. The container closure system, including the stopper and crimp seal, must prevent water vapor ingress. Storage temperature varies from controlled room temperature to refrigerated or frozen conditions, depending on the formulation. Humidity-controlled environments are essential because even brief exposure to ambient air can degrade the product.
Stability of a lyophilized product depends on its glass transition temperature, the temperature at which the amorphous cake transitions from a glassy to a rubbery state. Storage below this temperature minimizes molecular mobility and slows chemical degradation. If the storage temperature exceeds the glass transition temperature, the cake may collapse, shrink, or become sticky. Accelerated stability studies at elevated temperatures and humidity help predict shelf life, but they do not always reflect real-time behavior. Residual moisture content also plays a critical role in long-term stability.
Reconstitution involves adding a suitable diluent, often sterile water or a buffer, to the dried cake. Gentle swirling or inversion helps dissolve the material without creating excessive foam. The time required for complete dissolution can range from seconds to several minutes and depends on the cake structure and the diluent. Improper reconstitution, such as vigorous shaking or using the wrong diluent, can cause protein aggregation or loss of activity. After reconstitution, the product may have a limited shelf life and should be used according to its labeling.
A typical cycle begins with freezing, which fixes the material into a solid and determines ice crystal size. Primary drying then raises heat under vacuum so ice sublimes, often near or below the collapse temperature of the formulation. Secondary drying removes bound water that remains after ice is gone, usually by gently warming the product. Each stage balances heat input against pressure to avoid melting or structural damage. Temperature probes and pressure sensors guide the transition between stages.
In practice, lyophilization is slower and more energy intensive than simple drying. Cycle times can range from hours to several days depending on load, container, and formulation. Amorphous materials may require excipients that help preserve structure during freezing and drying. The method is widely used for biological materials, pharmaceuticals, and foods where heat drying would cause unacceptable change. Open questions remain about scaling cycles between laboratory and production equipment, and this gap affects technology transfer.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white porous cake | Color depends on formulation. |
| Typical storage temperature | 2–8 °C | Refrigerated for many biologics. |
| Residual moisture | <1% to 3% | Low moisture improves stability. |
| Container | Sealed glass vial | Often with rubber stopper and aluminum crimp. |
| Reconstitution time | Seconds to minutes | Varies with cake density and diluent. |
Lyophilized solids are often hygroscopic, so handling occurs in controlled low-humidity areas or glove boxes when the material is exposed. Vials remain sealed with elastomeric stoppers and aluminum crimps until use, because airborne moisture can raise residual water and shorten shelf life. The porous cake is fragile and may crack, shrink, or powder during transport. Personnel typically avoid repeated warming and cooling of sealed units, which can draw moisture through closures. These practices aim to preserve the low water content achieved during drying.
Storage conditions depend on the formulation and the intended shelf life. Many pharmaceutical and biological freeze-dried products are kept at 2–8 °C, while some stable foods and reagents tolerate room temperature. Others require −20 °C or colder to slow chemical degradation or aggregation. Protection from light and oxygen is common because oxidation can continue in the dry state. Stability studies usually monitor potency, appearance, moisture, and reconstitution time over months or years. Predictions from accelerated studies are useful but may not fully capture real-time changes.
Quality control for freeze-dried lots combines visual inspection with instrumental tests. Cake appearance, color, and shrinkage are recorded against a reference, while residual moisture is measured by Karl Fischer titration or loss on drying. Thermal analysis can reveal phase transitions and crystallization events, and X-ray diffraction distinguishes amorphous from crystalline solids. Microbiological tests and container closure integrity checks are also routine for sterile products. Analytical methods must be validated for the matrix, because excipients and low moisture can affect accuracy. Open questions include how best to predict long-term stability from short-term data.
Lyophilization is a dehydration process that removes water from a frozen material by sublimation under low pressure. The material is first frozen so that water becomes ice; then the surrounding pressure is lowered below the vapor pressure of ice. Heat is applied gently so ice changes directly to vapor without passing through a bulk liquid phase. The vapor is collected on a cold condenser, leaving a dry porous matrix. This process differs from simple evaporation because the material remains frozen during the main drying stage.
The process usually has three stages: freezing, primary drying, and secondary drying. Freezing sets the ice crystal structure and can determine pore size in the final cake. Primary drying removes free ice by sublimation at low pressure and low shelf temperature. Secondary drying removes bound water by raising the shelf temperature, although some water may remain as part of the solid. Cycle parameters depend on formulation, fill volume, vial type, and equipment performance.
The physical chemistry of freezing influences whether a formulation forms an amorphous glass or a crystalline solid. Amorphous systems can collapse if product temperature rises above the glass transition temperature of the freeze concentrate. Crystalline systems may show eutectic melting, where ice and solute melt together at a fixed temperature. Formulators add bulking agents, lyoprotectants, and buffers to preserve structure and biological activity. The optimum cycle keeps product temperature below critical thresholds during primary drying while allowing efficient sublimation.
Quality control for lyophilized materials includes visual inspection, residual moisture measurement, and reconstitution testing. Cake appearance can reveal process problems such as collapse, shrinkage, or meltback, although appearance alone does not prove potency. Residual moisture is commonly measured by Karl Fischer titration or by loss on drying. Reconstitution time is checked because a slow or incomplete dissolve can indicate a change in pore structure. Stability studies track these attributes over time under defined temperature and humidity conditions.
Analytical methods for lyophilized solids must account for the low moisture content and the fragile cake. Karl Fischer titration is widely used for water content, while near-infrared spectroscopy can measure moisture non-destructively in sealed containers. X-ray diffraction and modulated differential scanning calorimetry help identify crystalline or amorphous phases. Residual solvent analysis may be needed if organic solvents were used during formulation. The combination of these methods supports batch release and long-term stability assessment.
Oclacitinib, sold under the brand name Apoquel among others, is a veterinary medication used in the control of atopic dermatitis and pruritus from allergic dermatitis in dogs at least 12 months of age. Chemically, it is a synthetic cyclohexylamino-pyrrolopyrimidine Janus kinase inhibitor (JAK inhibitor) that is relatively selective for JAK1. It inhibits signal transduction when the JAK is activated and thereby helps downregulate expression of inflammatory cytokine. Oclacitinib was approved for use in the United States in 2013 and in the European Union in 2023. A flavored chewable form was approved for use in the United States in 2023.
Bush and Mikhail Gorbachev meet in Helsinki, Finland and issue a joint declaration condemning the invasion of Kuwait. October 1: The Rwandan Civil War begins, between the RPF and the Rwandan government. October 3: Germany is reunified. October 4: The Mozambican Civil War ends with the defeat of the anti-communist RENAMO, allowing the ruling Marxist party, FRELIMO, to remain in power. October 15: Mikhail Gorbachev is awarded the Nobel Peace Prize. October 25: The Kazakhstan Soviet Socialist Republic issues a declaration on state sovereignty which gives republic's operations precedence over all others. It is later renamed the following year on December 10, 1991, to the Republic of Kazakhstan. November 2: The Transnistria War begins in Moldova. November 21: The Paris Charter is ratified by the Organization for Security and Co-operation in Europe. December 23: Slovenia holds an independence referendum with a majority voting in favor.
== Abuse == There have been reports of incidents of abuse regarding forced insemination with sperm samples bought online. Further abuse of sperm banks comes from the fertility clinic staff themselves. There have been a number of reports of staff at sperm banks and fertility clinics providing their own sperm in place of donor sperm. There have also been cases in which men have claimed their sperm sample was used by a clinic to inseminate a woman without his consent. This has led to cases of malpractice, and in some states, lobbying to create fertility fraud laws. These incidents have also led to outcry by people who had been conceived by such incidents, raising concerns of consanguinity, as well as the simple right to know who their siblings and biologic parents are.
=== EC 2.7.1: Phosphotransferases with an alcohol group as acceptor === EC 2.7.1.1: hexokinase EC 2.7.1.2: glucokinase EC 2.7.1.3: ketohexokinase EC 2.7.1.4: fructokinase EC 2.7.1.5: rhamnulokinase EC 2.7.1.6: galactokinase EC 2.7.1.7: mannokinase EC 2.7.1.8: glucosamine kinase EC 2.7.1.9: deleted EC 2.7.1.10: phosphoglucokinase EC 2.7.1.11: 6-phosphofructokinase EC 2.7.1.12: gluconokinase EC 2.7.1.13: dehydrogluconokinase EC 2.7.1.14: sedoheptulokinase EC 2.7.1.15: ribokinase EC 2.7.1.16: ribulokinase EC 2.7.1.17: xylulokinase EC 2.7.1.18: phosphoribokinase EC 2.7.1.19: phosphoribulokinase EC 2.7.1.20: adenosine kinase EC 2.7.1.21: thymidine kinase EC 2.7.1.22: ribosylnicotinamide kinase EC 2.7.1.23: NAD+ kinase EC 2.7.1.24: dephospho-CoA kinase EC 2.7.1.25: adenylyl-sulfate kinase EC 2.7.1.26: riboflavin kinase EC 2.7.1.27: erythritol kinase (D-erythritol 4-phosphate-forming) EC 2.7.1.28: triokinase EC 2.7.1.29: glycerone kinase EC 2.7.1.30: glycerol kinase EC 2.7.1.31: glycerate kinase EC 2.7.1.32: choline kinase EC 2.7.1.33: pantothenate kinase EC 2.7.1.34: pantetheine kinase EC 2.7.1.35: pyridoxal kinase EC 2.7.1.36: mevalonate kinase EC 2.7.1.37: now divided into EC 2.7.11.1, EC 2.7.11.8, EC 2.7.11.9, EC 2.7.11.10, EC 2.7.11.11, EC 2.7.11.12, EC 2.7.11.13, EC 2.7.11.21, EC 2.7.11.22, EC 2.7.11.24, EC 2.7.11.25, EC 2.7.11.30 and EC 2.7.12.1 EC 2.7.1.38: now EC 2.7.11.19, phosphorylase kinase EC 2.7.1.39: homoserine kinase EC 2.7.1.40: pyruvate kinase EC 2.7.1.41: glucose-1-phosphate phosphodismutase EC 2.7.1.42: riboflavin phosphotransferase EC 2.7.1.43: glucuronokinase EC 2.7.1.44: galacturonokinase EC 2.7.1.45: 2-dehydro-3-deoxygluconokinase EC 2.7.1.46: L-arabinokinase EC 2.7.1.47: D-ribulokinase EC 2.7.1.48: uridine kinase EC 2.7.1.49: hydroxymethylpyrimidine kinase EC 2.7.1.50: hydroxyethylthiazole kinase EC 2.7.1.51: L-fuculokinase EC 2.7.1.52: fucokinase EC 2.7.1.53: L-xylulokinase EC 2.7.1.54: D-arabinokinase EC 2.7.1.55: allose kinase EC 2.7.1.56: 1-phosphofructokinase EC 2.7.1.57: deleted EC 2.7.1.58: 2-dehydro-3-deoxygalactonokinase EC 2.7.1.59: N-acetylglucosamine kinase EC 2.7.1.60: N-acylmannosamine kinase EC 2.7.1.61: acyl-phosphate—hexose phosphotransferase EC 2.7.1.62: Phosphoramidate-hexose phosphotransferase EC 2.7.1.63: polyphosphate—glucose phosphotransferase EC 2.7.1.64: inositol 3-kinase EC 2.7.1.65: scyllo-inosamine 4-kinase EC 2.7.1.66: undecaprenol kinase EC 2.7.1.67: 1-phosphatidylinositol 4-kinase EC 2.7.1.68: 1-phosphatidylinositol-4-phosphate 5-kinase EC 2.7.1.69: now covered by EC 2.7.1.191, EC 2.7.1.192, EC 2.7.1.193, EC 2.7.1.194, EC 2.7.1.195, EC 2.7.1.196, EC 2.7.1.197, EC 2.7.1.198, EC 2.7.1.199, EC 2.7.1.200 EC 2.7.1.20, EC 2.7.1.202, EC 2.7.1.203, EC 2.7.1.204, EC 2.7.1.205, EC 2.7.1.206, EC 2.7.1.207 and EC 2.7.1.208 EC 2.7.1.70: Now included in EC 2.7.11.1, non-specific serine/threonine protein kinase EC 2.7.1.71: shikimate kinase EC 2.7.1.72: streptomycin 6-kinase EC 2.7.1.73: inosine kinase EC 2.7.1.74: deoxycytidine kinase EC 2.7.1.75: Now EC 2.7.1.21 thymidine kinase EC 2.7.1.76: deoxyadenosine kinase EC 2.7.1.77: nucleoside phosphotransferase EC 2.7.1.78: polynucleotide 5′-hydroxyl-kinase EC 2.7.1.79: diphosphate—glycerol phosphotransferase EC 2.7.1.80: diphosphate—serine phosphotransferase EC 2.7.1.81: hydroxylysine kinase EC 2.7.1.82: ethanolamine kinase EC 2.7.1.83: pseudouridine kinase EC 2.7.1.84: alkylglycerone kinase EC 2.7.1.85: β-glucoside kinase EC 2.7.1.86: NADH kinase EC 2.7.1.87: streptomycin 3′′-kinase EC 2.7.1.88: dihydrostreptomycin-6-phosphate 3′α-kinase EC 2.7.1.89: thiamine kinase EC 2.7.1.90: diphosphate—fructose-6-phosphate 1-phosphotransferase EC 2.7.1.91: sphinganine kinase EC 2.7.1.92: 5-dehydro-2-deoxygluconokinase EC 2.7.1.93: alkylglycerol kinase EC 2.7.1.94: acylglycerol kinase EC 2.7.1.95: kanamycin kinase EC 2.7.1.96: deleted, Now included with EC 2.7.1.86 NADH kinase EC 2.7.1.97: deleted, Identical with EC 2.7.11.14, rhodopsin kinase EC 2.7.1.98: deleted EC 2.7.1.99: Now EC 2.7.11.2, [pyruvate dehydrogenase (acetyl-transferring)] kinase EC 2.7.1.100: S-methyl-5-thioribose kinase EC 2.7.1.101: tagatose kinase EC 2.7.1.102: hamamelose kinase EC 2.7.1.103: viomycin kinase EC 2.7.1.104: Now EC 2.7.99.1, triphosphate—protein phosphotransferase EC 2.7.1.105: 6-phosphofructo-2-kinase EC 2.7.1.106: glucose-1,6-bisphosphate synthase EC 2.7.1.107: diacylglycerol kinase EC 2.7.1.108: dolichol kinase EC 2.7.1.109: Now EC 2.7.11.31, [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase EC 2.7.1.110: Now EC 2.7.11.3, dephospho-(reductase kinase) kinase EC 2.7.1.111: Now listed as EC 2.7.11.27, [acetyl-CoA carboxylase] kinase EC 2.7.1.112: Now EC 2.7.10.2, non-specific protein-tyrosine kinase EC 2.7.1.113: deoxyguanosine kinase EC 2.7.1.114: AMP—thymidine kinase EC 2.7.1.115: Now EC 2.7.11.4, (3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)) kinase EC 2.7.1.116: Now EC 2.7.11.5, [isocitrate dehydrogenase (NADP+)] kinase EC 2.7.1.117: Now EC 2.7.11.18, myosin-light-chain kinase EC 2.7.1.118: ADP—thymidine kinase EC 2.7.1.119: hygromycin-B 7′′-O-kinase EC 2.7.1.120: Now EC 2.7.11.17, Ca2+/calmodulin-dependent protein kinase EC 2.7.1.121: phosphoenolpyruvate—glycerone phosphotransferase EC 2.7.1.122: xylitol kinase EC 2.7.1.123: Now EC 2.7.11.17, Ca2+/calmodulin-dependent protein kinase EC 2.7.1.124: Now EC 2.7.11.6, [tyrosine 3-monooxygenase] kinase EC 2.7.1.125: Now EC 2.7.11.14, rhodopsin kinase EC 2.7.1.126: Now EC 2.7.11.15, β-adrenergic-receptor kinase EC 2.7.1.127: inositol-trisphosphate 3-kinase EC 2.7.1.128: Now EC 2.7.11.27, [acetyl-CoA carboxylase] kinase EC 2.7.1.129: Now EC 2.7.11.7, myosin-heavy-chain kinase EC 2.7.1.130: tetraacyldisaccharide 4′-kinase EC 2.7.1.131: Now EC 2.7.11.29, low-density-lipoprotein receptor kinase EC 2.7.1.132: Now EC 2.7.11.28, tropomyosin kinase EC 2.7.1.133: Now included with EC 2.7.1.134, inositol-tetrakisphosphate 1-kinase EC 2.7.1.134: inositol-tetrakisphosphate 1-kinase EC 2.7.1.135: Now EC 2.7.11.26, tau-protein kinase EC 2.7.1.136: macrolide 2′-kinase EC 2.7.1.137: phosphatidylinositol 3-kinase EC 2.7.1.138: ceramide kinase EC 2.7.1.139: Now included with EC 2.7.1.134, inositol-tetrakisphosphate 1-kinase EC 2.7.1.140: inositol-tetrakisphosphate 5-kinase EC 2.7.1.141: Now EC 2.7.11.23, [RNA-polymerase]-subunit kinase EC 2.7.1.142: glycerol-3-phosphate—glucose phosphotransferase EC 2.7.1.143: diphosphate-purine nucleoside kinase EC 2.7.1.144: tagatose-6-phosphate kinase EC 2.7.1.145: deoxynucleoside kinase EC 2.7.1.146: ADP-dependent phosphofructokinase EC 2.7.1.147: ADP-dependent glucokinase EC 2.7.1.148: 4-(cytidine 5′-diphospho)-2-C-methyl-D-erythritol kinase EC 2.7.1.149: 1-phosphatidylinositol-5-phosphate 4-kinase EC 2.7.1.150: 1-phosphatidylinositol-3-phosphate 5-kinase EC 2.7.1.151: inositol-polyphosphate multikinase EC 2.7.1.152: Now EC 2.7.4.21, inositol-hexakisphosphate kinase EC 2.7.1.153: phosphatidylinositol-4,5-bisphosphate 3-kinase EC 2.7.1.154: phosphatidylinositol-4-phosphate 3-kinase EC 2.7.1.155: Now EC 2.7.4.24, diphosphoinositol-pentakisphosphate kinase EC 2.7.1.156: adenosylcobinamide kinase EC 2.7.1.157: N-acetylgalactosamine kinase EC 2.7.1.158: inositol-pentakisphosphate 2-kinase EC 2.7.1.159: inositol-1,3,4-trisphosphate 5/6-kinase EC 2.7.1.160: 2′-phosphotransferase EC 2.7.1.161: CTP-dependent riboflavin kinase EC 2.7.1.162: N-acetylhexosamine 1-kinase EC 2.7.1.163: hygromycin B 4-O-kinase EC 2.7.1.164: O-phosphoseryl-tRNASec kinase EC 2.7.1.165: glycerate 2-kinase EC 2.7.1.166: 3-deoxy-D-manno-octulosonic acid kinase EC 2.7.1.167: D-glycero-β-D-manno-heptose-7-phosphate kinase EC 2.7.1.168: D-glycero-α-D-manno-heptose-7-phosphate kinase EC 2.7.1.169: pantoate kinase EC 2.7.1.170: anhydro-N-acetylmuramic acid kinase EC 2.7.1.171: protein-fructosamine 3-kinase EC 2.7.1.172: protein-ribulosamine 3-kinase EC 2.7.1.173: nicotinate riboside kinase EC 2.7.1.174: diacylglycerol kinase (CTP dependent) EC 2.7.1.175: maltokinase EC 2.7.1.176: UDP-N-acetylglucosamine kinase EC 2.7.1.177: L-threonine kinase EC 2.7.1.178: 2-dehydro-3-deoxyglucono/galactono-kinase EC 2.7.1.179: kanosamine kinase EC 2.7.1.180: FAD:protein FMN transferase EC 2.7.1.181: polymannosyl GlcNAc-diphospho-ditrans,octacis-undecaprenol kinase EC 2.7.1.182: phytol kinase EC 2.7.1.183: glycoprotein-mannosyl O6-kinase EC 2.7.1.184: sulfofructose kinase EC 2.7.1.185: mevalonate 3-kinase EC 2.7.1.186: mevalonate-3-phosphate 5-kinase EC 2.7.1.187: acarbose 7IV-phosphotransferase EC 2.7.1.188: 2-epi-5-epi-valiolone 7-kinase EC 2.7.1.189: autoinducer-2 kinase EC 2.7.1.190: aminoglycoside 2′′-phosphotransferase EC 2.7.1.191: protein-N π-phosphohistidine—D-mannose phosphotransferase EC 2.7.1.192: protein-N π-phosphohistidine—N-acetylmuramate phosphotransferase EC 2.7.1.193: protein-N π-phosphohistidine—N-acetyl-D-glucosamine phosphotransferase EC 2.7.1.194: protein-N π-phosphohistidine—L-ascorbate phosphotransferase EC 2.7.1.195: protein-N π-phosphohistidine—2-O-α-mannosyl-D-glycerate phosphotransferase EC 2.7.1.196: protein-N π-phosphohistidine—N,N′-diacetylchitobiose phosphotransferase EC 2.7.1.197: protein-Nπ'-phosphohistidine—D-mannitol phosphotransferase EC 2.7.1.198: protein-N π-phosphohistidine—D-sorbitol phosphotransferase EC 2.7.1.199: protein-N π-phosphohistidine—D-glucose phosphotransferase EC 2.7.1.200: protein-N π-phosphohistidine—galactitol phosphotransferase EC 2.7.1.201: protein-N π-phosphohistidine—trehalose phosphotransferase EC 2.7.1.202: protein-N π-phosphohistidine—D-fructose phosphotransferase EC 2.7.1.203: protein-N π-phosphohistidine—D-glucosaminate phosphotransferase EC 2.7.1.204: protein-N π-phosphohistidine—D-galactose phosphotransferase EC 2.7.1.205: protein-N π-phosphohistidine—cellobiose phosphotransferase EC 2.7.1.206: protein-N π-phosphohistidine—L-sorbose phosphotransferase EC 2.7.1.207: protein-N π-phosphohistidine—lactose phosphotransferase EC 2.7.1.208: protein-N π-phosphohistidine—maltose phosphotransferase EC 2.7.1.209: L-erythrulose 1-kinase EC 2.7.1.210: D-erythrulose 4-kinase EC 2.7.1.211: protein-N π-phosphohistidine—sucrose phosphotransferase EC 2.7.1.212: α-D-ribose-1-phosphate 5-kinase (ADP) EC 2.7.1.213: cytidine kinase EC 2.7.1.214: C7-cyclitol 7-kinase EC 2.7.1.215: erythritol kinase (D-erythritol 1-phosphate-forming) EC 2.7.1.216: farnesol kinase EC 2.7.1.217: 3-dehydrotetronate 4-kinase EC 2.7.1.218: fructoselysine 6-kinase EC 2.7.1.219: D-threonate 4-kinase EC 2.7.1.220: D-erythronate 4-kinase EC 2.7.1.221: N-acetylmuramate 1-kinase EC 2.7.1.222: 4-hydroxytryptamine kinase EC 2.7.1.223: aminoimidazole riboside kinase EC 2.7.1.224: cytidine diphosphoramidate kinase EC 2.7.1.225: L-serine kinase (ATP) EC 2.7.1.226: L-serine kinase (ADP) EC 2.7.1.227: inositol phosphorylceramide synthase EC 2.7.1.228: mannosyl-inositol-phosphoceramide inositolphosphotransferase EC 2.7.1.229: deoxyribokinase EC 2.7.1.230: amicoumacin kinase EC 2.7.1.231: 3-oxoisoapionate kinase EC 2.7.1.232: levoglucosan kinase EC 2.7.1.233: apulose kinase
Sources: en.wikipedia.org
These are mostly single-die LEDs used as indicators, and they come in various sizes from 1.8 mm to 10 mm, through-hole and surface mount packages. Typical current ratings range from around 1 mA to above 20 mA. LED's can be soldered to a flexible PCB strip to form LED tape popularly used for decoration. Common package shapes include round, with a domed or flat top, rectangular with a flat top (as used in bar-graph displays), and triangular or square with a flat top. The encapsulation may also be clear or tinted to improve contrast and viewing angle. Infrared devices may have a black tint to block visible light while passing infrared radiation, such as the Osram SFH 4546. 5 V and 12 V LEDs are ordinary miniature LEDs that have a series resistor for direct connection to a 5 V or 12 V supply.
==== Member of the Royal Victorian Order (MVO) ==== Russell Adams, , Custodian of California Stores, Royal Collection, Royal Household. Captain Andrew Mark Aspden, Royal Navy, lately Principal Private Secretary to The Duke and Duchess of Edinburgh. Ian Charles Bartlett, Clerk of the Works, Westminster Abbey, on the occasion of the Coronation of Their Majesties The King and The Queen. Nicholas John Birch, Sergeant, Metropolitan Police Service. For services to Royalty and Specialist Protection. Ian Leslie Bullock, , Security Officer Team Leader, Palace of Holyroodhouse. Emma Jane Clarke, Secretary, Royal Farms, Windsor. Nicola Charlotte Craig, Royal Borough of Windsor and Maidenhead, on the occasion of the Coronation Concert. Andrew John Cranidge, Superintendent, Thames Valley Police, on the occasion of the Coronation Concert. Anne Maria Curran, Personal and Administration Assistant, Superintendent's Office, Windsor Castle. Sarah Louise Davis, Head of Press and Marketing, Royal Collection, Royal Household. Julie Elizabeth Denby, lately Deputy Clerk/Administrator, Greater Manchester Lieutenancy. Michael Robert Duncan, lately Special Project Advisor, Royal Household, on the occasion of the Coronation of Their Majesties The King and The Queen. Hannah Elizabeth Evans, Programme Manager, Household of The Princess Royal. David Irwin Foy, Stud Groom, Royal Paddocks, Hampton Court Palace. Christopher William Andrew Hallworth, Senior Business Applications and Infrastructure Manager, Royal Collection, Royal Household.
== Record and specimen retention == CLIA and the College of American Pathologists (CAP) have written policies for the minimum period that laboratories should keep laboratory records and materials, with some examples as follows:
Sources: en.wikipedia.org
Lyophilized products should be stored in airtight containers, protected from moisture and light, at the temperature specified by the manufacturer. Many require refrigeration at 2–8 °C, while some need frozen storage. Always check the product label for specific conditions.
Moisture can cause the porous cake to collapse, increase molecular mobility, and accelerate chemical degradation. It may also promote microbial growth if the product lacks preservatives. Proper sealing and handling are essential to maintain stability.
Some formulations contain labile biological molecules that degrade even in the dry state at higher temperatures. Others have a low glass transition temperature, meaning the cake can soften or collapse at room temperature. Cold storage reduces molecular motion and slows degradation.
Primary drying removes ice by sublimation under vacuum. Secondary drying removes water that is bound to the material, often by warming the product after most ice has left. Both stages occur below temperatures that would cause unwanted melting.